1700003M02Rik Inhibitors
Chemical inhibitors of the 1700003M02Rik protein operate through various biochemical pathways to inhibit its activity. Wortmannin and LY294002 exert their effects by targeting phosphoinositide 3-kinases (PI3K), which play a pivotal role in the PI3K/AKT signaling pathway. The inhibition of PI3K by these compounds can result in reduced phosphorylation and activation of downstream proteins, including 1700003M02Rik. Rapamycin, although different in its mode of action, also disrupts the PI3K/AKT/mTOR pathway by binding to FKBP12 and inhibiting mTOR complex 1, which can decrease the activity of proteins regulated by this pathway. Triciribine, on the other hand, directly inhibits the phosphorylation of AKT, a kinase that is upstream of 1700003M02Rik in the signaling cascade.
The MAPK/ERK pathway is another critical regulator of 1700003M02Rik, and it is targeted by U0126 and PD98059, which are selective inhibitors of MEK1/2. By preventing the activation of MEK1/2, these inhibitors can suppress the activation of the ERK pathway and consequently the activity of 1700003M02Rik. SP600125 and SB203580 are inhibitors that target other MAP kinase pathways, specifically the JNK pathway and the p38 MAP kinase pathway, respectively. Inhibition of these kinases by SP600125 and SB203580 can lead to reduced stress response signaling and can alter the functional activity of 1700003M02Rik. Erlotinib and Gefitinib focus on the inhibition of the epidermal growth factor receptor (EGFR) tyrosine kinase, which, upon inhibition, can lead to a disruption in downstream signaling that regulates the activity of 1700003M02Rik. Lastly, the broad-spectrum kinase inhibitor, Staurosporine, and the multi-kinase inhibitor, Sorafenib, can inhibit a wide range of kinases within various signaling pathways, including pathways that regulate the activity of 1700003M02Rik, thus leading to a decrease in its activity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a covalent inhibitor of phosphoinositide 3-kinases (PI3K). By inhibiting PI3K, it prevents the phosphorylation and activation of downstream proteins, including the 1700003M02Rik protein which is dependent on PI3K signaling for its activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 selectively inhibits PI3K, leading to reduced phosphorylation and activity of downstream proteins in the PI3K/AKT pathway, potentially including the 1700003M02Rik protein whose activity is regulated through this pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin binds to FKBP12 and inhibits mTOR complex 1, a component of the PI3K/AKT/mTOR pathway. Since the 1700003M02Rik protein is a downstream effector in this pathway, its activity can be inhibited by the disruption caused by rapamycin. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $102.00 $138.00 | 14 | |
Triciribine directly inhibits AKT phosphorylation and activation. The 1700003M02Rik protein, which operates downstream of AKT, would have its function inhibited due to the blockade of AKT signaling. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is a selective inhibitor of MEK1/2, which prevents the activation of the ERK pathway. The 1700003M02Rik protein, which may be regulated by the ERK pathway, would be functionally inhibited by the prevention of MEK1/2 activation. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 inhibits MEK1/2, which are upstream of ERK in the MAPK pathway. Functional inhibition of the 1700003M02Rik protein can occur due to reduced activity in the MAPK pathway caused by PD98059. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of the JNK pathway. By inhibiting JNK, it can interfere with signaling pathways that regulate the activity of the 1700003M02Rik protein, leading to its functional inhibition. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 specifically inhibits p38 MAP kinase, which can regulate stress response signaling pathways that may influence the function of the 1700003M02Rik protein, leading to its inhibition. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $85.00 $132.00 $287.00 $495.00 $3752.00 | 42 | |
Erlotinib inhibits the epidermal growth factor receptor (EGFR) tyrosine kinase. Inhibition of EGFR can lead to downstream signaling disruption that inhibits the function of proteins such as 1700003M02Rik. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Gefitinib is an EGFR tyrosine kinase inhibitor. By inhibiting EGFR, gefitinib prevents downstream signaling that can functionally inhibit proteins regulated by this pathway, potentially including the 1700003M02Rik protein. | ||||||